CLNN Stock Overview
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Clene Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.04 |
| 52 Week High | US$9.20 |
| 52 Week Low | US$2.57 |
| Beta | 0.46 |
| 1 Month Change | -5.59% |
| 3 Month Change | -35.87% |
| 1 Year Change | -64.80% |
| 3 Year Change | -94.31% |
| 5 Year Change | -98.57% |
| Change since IPO | -98.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| CLNN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.0% | 5.7% | 7.1% |
| 1Y | -64.8% | -4.2% | 7.7% |
Return vs Industry: CLNN underperformed the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: CLNN underperformed the US Market which returned 7.7% over the past year.
Price Volatility
| CLNN volatility | |
|---|---|
| CLNN Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: CLNN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CLNN's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 76 | Rob Etherington | clene.com |
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain’s energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson’s Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution.
Clene Inc. Fundamentals Summary
| CLNN fundamental statistics | |
|---|---|
| Market cap | US$26.15m |
| Earnings (TTM) | -US$39.40m |
| Revenue (TTM) | US$342.00k |
76.7x
P/S Ratio-0.7x
P/E RatioIs CLNN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLNN income statement (TTM) | |
|---|---|
| Revenue | US$342.00k |
| Cost of Revenue | US$70.00k |
| Gross Profit | US$272.00k |
| Other Expenses | US$39.67m |
| Earnings | -US$39.40m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.56 |
| Gross Margin | 79.53% |
| Net Profit Margin | -11,520.47% |
| Debt/Equity Ratio | -178.2% |
How did CLNN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/29 21:46 |
| End of Day Share Price | 2025/04/29 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Clene Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bruce Jackson | Benchmark Company |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |
| Jason Kolbert | D. Boral Capital LLC. |